<p>根据 Envestnet Asset Management Inc.最近向证券交易委员会的提交文件，该公司在第三季度减少了对 Jazz Pharmaceuticals PLC（NASDAQ:JAZZ - 免费报告）9.5% 的持股。该公司在此期间出售了 10,744 股后，持有 102,181 股这家专业制药公司的股票。Envestnet Asset Management Inc.在最近的报告期末持有 Jazz Pharmaceuticals 0.17% 的股份，价值 13,467,000 美元。</p>
<p>获取 <strong>Jazz Pharmaceuticals</strong> 的提醒：</p>
<ul>
<li>Zymeworks 为长期投资者提供了希望</li>
</ul>
<p>其他一些对冲基金最近也增加或减少了对 JAZZ 的持股。LSV Asset Management 在第二季度将其在 Jazz Pharmaceuticals 的股份增加了 3.6%。LSV Asset Management 现在持有 2,553,742 股这家专业制药公司的股票，价值 271,003,000 美元，此前在上个季度又收购了 87,576 股。Ameriprise Financial Inc.在第二季度将其在 Jazz Pharmaceuticals 的股份增加了 11.4%。Ameriprise Financial Inc.现在持有 1,867,399 股这家专业制药公司的股票，价值 198,159,000 美元，此前在上个季度又购买了 191,637 股。摩根大通在第二季度将其在 Jazz Pharmaceuticals 的股份增加了 3.6%。摩根大通现在持有 1,721,294 股这家专业制药公司的股票，价值 182,664,000 美元，此前在上个季度又收购了 59,252 股。Vestal Point Capital LP 在第二季度购买了 Jazz Pharmaceuticals 的新股份，价值约 127,344,000 美元。最后，Geode Capital Management LLC 在第二季度将其在 Jazz Pharmaceuticals 的股份增加了 1.5%。Geode Capital Management LLC 现在持有 1,171,755 股这家专业制药公司的股票，价值 124,366,000 美元，此前在此期间又收购了 16,757 股。机构投资者和对冲基金持有该公司 89.14% 的股份。</p>
<h2>Jazz Pharmaceuticals 股票上涨 0.0%</h2>
<p>JAZZ 周二开盘价为 166.31 美元。该公司的债务与股本比率为 1.09，速动比率为 1.44，流动比率为 1.65。Jazz Pharmaceuticals PLC 的 52 周低点为 95.49 美元，52 周高点为 182.99 美元。该公司的 50 日移动平均线为 167.54 美元，200 日移动平均线为 147.79 美元。该股票的市值为 101 亿美元，市盈率为-27.40，市盈增长比率为 0.89，贝塔值为 0.26。</p>
<h2>分析师评级上调与下调</h2>
<ul>
<li>顶级大麻股票：投资机会众多（你并没有错过机会）</li>
</ul>
<p>几家研究公司对 JAZZ 发布了报告。Weiss Ratings 在 12 月 29 日的研究报告中重申了对 Jazz Pharmaceuticals 股票的 “卖出（d+）” 评级。美国银行在 11 月 18 日的报告中将 Jazz Pharmaceuticals 的目标价从 230.00 美元上调至 247.00 美元，并给予该股票 “买入” 评级。Truist Financial 在 1 月 12 日的研究报告中将 Jazz Pharmaceuticals 的目标价从 220.00 美元上调至 230.00 美元，并给予该股票 “买入” 评级。Wall Street Zen 在 11 月 8 日的报告中将 Jazz Pharmaceuticals 的评级从 “持有” 上调至 “强力买入”。最后，富国银行在 11 月 18 日的研究报告中将 Jazz Pharmaceuticals 的目标价从 170.00 美元上调至 235.00 美元，并给予该股票 “超配” 评级。十四位研究分析师对该股票给予了买入评级，三位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该股票的共识评级为 “适度买入”，平均目标价为 205.67 美元。</p>
<p><strong>获取我们对 JAZZ 的最新分析</strong></p>
<h2>Jazz Pharmaceuticals 的内部买卖</h2>
<p>在其他 Jazz Pharmaceuticals 的新闻中，董事 Bruce C. Cozadd 在 11 月 26 日的交易中出售了 77,500 股 Jazz Pharmaceuticals 的股票。这些股票以 177.81 美元的平均价格出售，总价值为 13,780,275.00 美元。交易完成后，该董事直接持有 393,332 股公司股票，价值 69,938,362.92 美元。这笔交易代表了其持股的 16.46% 的减少。该出售在向 SEC 的文件中披露，文件可在此链接查看。此外，SVP Mary Elizabeth Henderson 在 12 月 9 日的交易中出售了 2,238 股公司的股票。这些股票以 169.51 美元的平均价格出售，总交易额为 379,363.38 美元。交易完成后，该高级副总裁持有公司 19,508 股，价值约 3,306,801.08 美元。这笔交易代表了其持股的 10.29% 的减少。该出售的披露信息可在 SEC 文件中找到。在过去三个月中，内部人士出售了 87,813 股公司股票，价值 15,564,549 美元。公司内部人士持有公司 4.30% 的股份。</p>
<h2>Jazz Pharmaceuticals 公司简介</h2>
<p>（免费报告）</p>
<p>Jazz Pharmaceuticals plc 是一家全球生物制药公司，专注于开发和商业化神经科学和肿瘤学领域的疗法。该公司的研发工作针对睡眠障碍、血液恶性肿瘤、罕见神经疾病和实体肿瘤等未满足的医疗需求。Jazz 的产品组合包括用于治疗嗜睡症、肝静脉阻塞病、急性髓性白血病和其他严重疾病的疗法。</p>
<p>Jazz Pharmaceuticals 的旗舰产品包括 Xyrem®（氧化钠）和 Xywav®（钙、镁、钾和氧化钠），用于治疗嗜睡症患者的肌肉无力和白天过度嗜睡。</p>
<h2>推荐故事</h2>
<ul>
<li>我们更看好的五只股票比爵士制药更好</li>
<li>你的银行账户不再安全</li>
<li>英伟达首席执行官发出大胆的特斯拉呼吁</li>
<li>在 2026 年 5 月之前购买这只黄金股票</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
<li>这只 15 美元的股票可能会成为 2026 年的第一只股票</li>
</ul>
<p><strong>想看看其他对爵士制药持有股份的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取爵士制药 PLC (NASDAQ:JAZZ - 免费报告) 的最新 13F 文件和内部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SkFaWg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SkFaWg"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在爵士制药吗？</h2>
<p>在考虑爵士制药之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而爵士制药并不在名单上。</p>
<p>虽然爵士制药目前在分析师中有中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

标普生物技术 ETF - SPDR

医疗业 ETF - Vanguard

生物科技 ETF - VanEck Vectors

<p>Envestnet Asset Management Inc. 在第三季度减少了对爵士制药的持股比例，下降了 9.5%，出售了 10,744 股。该公司目前持有 102,181 股，价值约为 1347 万美元。其他对冲基金也调整了在爵士制药的持仓。该股票开盘价为 166.31 美元，市值为 101 亿美元。分析师的评级意见不一，普遍共识为 “适度买入”，平均目标价为 205.67 美元。最近的内部交易包括董事 Bruce C. Cozadd 出售了 77,500 股，交易金额约为 1378 万美元</p>

<p>Envestnet Asset Management Inc. lessened its stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 9.5% during the third quarter, according to its most recent filing with the Securities &amp; Exchange Commission. The firm owned 102,181 shares of the specialty pharmaceutical company's stock after selling 10,744 shares during the period. Envestnet Asset Management Inc. owned 0.17% of Jazz Pharmaceuticals worth $13,467,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>根据 Envestnet Asset Management Inc.最近向证券交易委员会的提交文件，该公司在第三季度减少了对 Jazz Pharmaceuticals PLC（NASDAQ:JAZZ - 免费报告）9.5% 的持股。该公司在此期间出售了 10,744 股后，持有 102,181 股这家专业制药公司的股票。Envestnet Asset Management Inc.在最近的报告期末持有 Jazz Pharmaceuticals 0.17% 的股份，价值 13,467,000 美元。</p>
</div><p>Get <strong>Jazz Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Jazz Pharmaceuticals</strong> 的提醒：</p>
</div><ul>
<li>Zymeworks Offers Hope for More than Just Long-Term Investors</li>
</ul>
<div class="lb-trans"><ul>
<li>Zymeworks 为长期投资者提供了希望</li>
</ul>
</div><p>A number of other hedge funds have also recently added to or reduced their stakes in JAZZ. LSV Asset Management increased its position in shares of Jazz Pharmaceuticals by 3.6% during the second quarter. LSV Asset Management now owns 2,553,742 shares of the specialty pharmaceutical company's stock worth $271,003,000 after acquiring an additional 87,576 shares in the last quarter. Ameriprise Financial Inc. increased its position in shares of Jazz Pharmaceuticals by 11.4% during the 2nd quarter. Ameriprise Financial Inc. now owns 1,867,399 shares of the specialty pharmaceutical company's stock valued at $198,159,000 after purchasing an additional 191,637 shares during the last quarter. JPMorgan Chase &amp; Co. boosted its stake in Jazz Pharmaceuticals by 3.6% in the second quarter. JPMorgan Chase &amp; Co. now owns 1,721,294 shares of the specialty pharmaceutical company's stock valued at $182,664,000 after acquiring an additional 59,252 shares during the last quarter. Vestal Point Capital LP purchased a new position in Jazz Pharmaceuticals in the second quarter valued at approximately $127,344,000. Finally, Geode Capital Management LLC raised its stake in Jazz Pharmaceuticals by 1.5% in the 2nd quarter. Geode Capital Management LLC now owns 1,171,755 shares of the specialty pharmaceutical company's stock valued at $124,366,000 after acquiring an additional 16,757 shares during the period. Institutional investors and hedge funds own 89.14% of the company's stock.</p>
<div class="lb-trans"><p>其他一些对冲基金最近也增加或减少了对 JAZZ 的持股。LSV Asset Management 在第二季度将其在 Jazz Pharmaceuticals 的股份增加了 3.6%。LSV Asset Management 现在持有 2,553,742 股这家专业制药公司的股票，价值 271,003,000 美元，此前在上个季度又收购了 87,576 股。Ameriprise Financial Inc.在第二季度将其在 Jazz Pharmaceuticals 的股份增加了 11.4%。Ameriprise Financial Inc.现在持有 1,867,399 股这家专业制药公司的股票，价值 198,159,000 美元，此前在上个季度又购买了 191,637 股。摩根大通在第二季度将其在 Jazz Pharmaceuticals 的股份增加了 3.6%。摩根大通现在持有 1,721,294 股这家专业制药公司的股票，价值 182,664,000 美元，此前在上个季度又收购了 59,252 股。Vestal Point Capital LP 在第二季度购买了 Jazz Pharmaceuticals 的新股份，价值约 127,344,000 美元。最后，Geode Capital Management LLC 在第二季度将其在 Jazz Pharmaceuticals 的股份增加了 1.5%。Geode Capital Management LLC 现在持有 1,171,755 股这家专业制药公司的股票，价值 124,366,000 美元，此前在此期间又收购了 16,757 股。机构投资者和对冲基金持有该公司 89.14% 的股份。</p>
</div><h2>Jazz Pharmaceuticals Stock Up 0.0%</h2>
<div class="lb-trans"><h2>Jazz Pharmaceuticals 股票上涨 0.0%</h2>
</div><p>JAZZ opened at $166.31 on Tuesday. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.44 and a current ratio of 1.65. Jazz Pharmaceuticals PLC has a fifty-two week low of $95.49 and a fifty-two week high of $182.99. The firm's fifty day moving average is $167.54 and its 200 day moving average is $147.79. The stock has a market cap of $10.10 billion, a price-to-earnings ratio of -27.40, a price-to-earnings-growth ratio of 0.89 and a beta of 0.26.</p>
<div class="lb-trans"><p>JAZZ 周二开盘价为 166.31 美元。该公司的债务与股本比率为 1.09，速动比率为 1.44，流动比率为 1.65。Jazz Pharmaceuticals PLC 的 52 周低点为 95.49 美元，52 周高点为 182.99 美元。该公司的 50 日移动平均线为 167.54 美元，200 日移动平均线为 147.79 美元。该股票的市值为 101 亿美元，市盈率为-27.40，市盈增长比率为 0.89，贝塔值为 0.26。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级上调与下调</h2>
</div><ul>
<li>Top Marijuana Stocks: Plenty of Investment Opportunities Abound (You're not Late to the Game)</li>
</ul>
<div class="lb-trans"><ul>
<li>顶级大麻股票：投资机会众多（你并没有错过机会）</li>
</ul>
</div><p>Several research firms have issued reports on JAZZ. Weiss Ratings restated a &#34;sell (d+)&#34; rating on shares of Jazz Pharmaceuticals in a research report on Monday, December 29th. Bank of America upped their price objective on Jazz Pharmaceuticals from $230.00 to $247.00 and gave the stock a &#34;buy&#34; rating in a report on Tuesday, November 18th. Truist Financial lifted their price target on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a &#34;buy&#34; rating in a research note on Monday, January 12th. Wall Street Zen upgraded shares of Jazz Pharmaceuticals from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a report on Saturday, November 8th. Finally, Wells Fargo &amp; Company upped their target price on shares of Jazz Pharmaceuticals from $170.00 to $235.00 and gave the stock an &#34;overweight&#34; rating in a research report on Tuesday, November 18th. Fourteen research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $205.67.</p>
<div class="lb-trans"><p>几家研究公司对 JAZZ 发布了报告。Weiss Ratings 在 12 月 29 日的研究报告中重申了对 Jazz Pharmaceuticals 股票的 “卖出（d+）” 评级。美国银行在 11 月 18 日的报告中将 Jazz Pharmaceuticals 的目标价从 230.00 美元上调至 247.00 美元，并给予该股票 “买入” 评级。Truist Financial 在 1 月 12 日的研究报告中将 Jazz Pharmaceuticals 的目标价从 220.00 美元上调至 230.00 美元，并给予该股票 “买入” 评级。Wall Street Zen 在 11 月 8 日的报告中将 Jazz Pharmaceuticals 的评级从 “持有” 上调至 “强力买入”。最后，富国银行在 11 月 18 日的研究报告中将 Jazz Pharmaceuticals 的目标价从 170.00 美元上调至 235.00 美元，并给予该股票 “超配” 评级。十四位研究分析师对该股票给予了买入评级，三位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该股票的共识评级为 “适度买入”，平均目标价为 205.67 美元。</p>
</div><p><strong>Get Our Latest Analysis on JAZZ</strong></p>
<div class="lb-trans"><p><strong>获取我们对 JAZZ 的最新分析</strong></p>
</div><h2>Insider Buying and Selling at Jazz Pharmaceuticals</h2>
<div class="lb-trans"><h2>Jazz Pharmaceuticals 的内部买卖</h2>
</div><p>In other Jazz Pharmaceuticals news, Director Bruce C. Cozadd sold 77,500 shares of Jazz Pharmaceuticals stock in a transaction on Wednesday, November 26th. The shares were sold at an average price of $177.81, for a total value of $13,780,275.00. Following the completion of the transaction, the director directly owned 393,332 shares of the company's stock, valued at $69,938,362.92. This trade represents a 16.46% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, SVP Mary Elizabeth Henderson sold 2,238 shares of the business's stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $169.51, for a total transaction of $379,363.38. Following the completion of the sale, the senior vice president owned 19,508 shares in the company, valued at approximately $3,306,801.08. This trade represents a 10.29% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 87,813 shares of company stock worth $15,564,549. Company insiders own 4.30% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Jazz Pharmaceuticals 的新闻中，董事 Bruce C. Cozadd 在 11 月 26 日的交易中出售了 77,500 股 Jazz Pharmaceuticals 的股票。这些股票以 177.81 美元的平均价格出售，总价值为 13,780,275.00 美元。交易完成后，该董事直接持有 393,332 股公司股票，价值 69,938,362.92 美元。这笔交易代表了其持股的 16.46% 的减少。该出售在向 SEC 的文件中披露，文件可在此链接查看。此外，SVP Mary Elizabeth Henderson 在 12 月 9 日的交易中出售了 2,238 股公司的股票。这些股票以 169.51 美元的平均价格出售，总交易额为 379,363.38 美元。交易完成后，该高级副总裁持有公司 19,508 股，价值约 3,306,801.08 美元。这笔交易代表了其持股的 10.29% 的减少。该出售的披露信息可在 SEC 文件中找到。在过去三个月中，内部人士出售了 87,813 股公司股票，价值 15,564,549 美元。公司内部人士持有公司 4.30% 的股份。</p>
</div><h2>Jazz Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Jazz Pharmaceuticals 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company's research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz's product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.</p>
<div class="lb-trans"><p>Jazz Pharmaceuticals plc 是一家全球生物制药公司，专注于开发和商业化神经科学和肿瘤学领域的疗法。该公司的研发工作针对睡眠障碍、血液恶性肿瘤、罕见神经疾病和实体肿瘤等未满足的医疗需求。Jazz 的产品组合包括用于治疗嗜睡症、肝静脉阻塞病、急性髓性白血病和其他严重疾病的疗法。</p>
</div><p>Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.</p>
<div class="lb-trans"><p>Jazz Pharmaceuticals 的旗舰产品包括 Xyrem®（氧化钠）和 Xywav®（钙、镁、钾和氧化钠），用于治疗嗜睡症患者的肌肉无力和白天过度嗜睡。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Jazz Pharmaceuticals</li>
<li>Your Bank Account Is No Longer Safe</li>
<li>Nvidia CEO Issues Bold Tesla Call</li>
<li>Buy this Gold Stock Before May 2026</li>
<li>What a Former CIA Agent Knows About the Coming Collapse</li>
<li>This $15 Stock Could Go Down as the #1 Stock of 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比爵士制药更好</li>
<li>你的银行账户不再安全</li>
<li>英伟达首席执行官发出大胆的特斯拉呼吁</li>
<li>在 2026 年 5 月之前购买这只黄金股票</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
<li>这只 15 美元的股票可能会成为 2026 年的第一只股票</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding JAZZ?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对爵士制药持有股份的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取爵士制药 PLC (NASDAQ:JAZZ - 免费报告) 的最新 13F 文件和内部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SkFaWg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=JAZZ"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Jazz Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在爵士制药吗？</h2>
</div><p>Before you consider Jazz Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑爵士制药之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Jazz Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而爵士制药并不在名单上。</p>
</div><p>While Jazz Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然爵士制药目前在分析师中有中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Envestnet Asset Management Inc. Sells 10,744 Shares of Jazz Pharmaceuticals PLC $JAZZ

Market Beat

动态生物技术与基因组 ETF - Invesco

纽交所高增长板生物技术指数 ETF - First Trust

爵士制药

纳斯达克生物科技指数 ETF - iShares Nasdaq

医药突破 ETF - ALPS

美国制药 ETF - iShares

Invesco Nasdaq Biotechnology ETF

医疗业 ETF - SPDR

2 倍做多纳斯达克生物技术 ETF - ProShares

Envestnet Asset Management Inc. 出售了 10,744 股爵士制药 PLC 的股票 $JAZZ